AMRN
Amarin Corporation plc [AMRN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AMRN Stock Summary
Top 10 Correlated ETFs
AMRN
Top 10 Correlated Stocks
AMRN
In the News
AMRN Financial details
Company Rating
Sell
Market Cap
391.24M
Income
-59.16M
Revenue
307.56M
Book val./share
1.35
Cash/share
0.79
Dividend
-
Dividend %
-
Employees
275
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
-7.25
Forward P/E
-
PEG
1.64
P/S
1.4
P/B
0.78
P/C
1.11
P/FCF
67.72
Quick Ratio
1.75
Current Ratio
2.8
Debt / Equity
0.02
LT Debt / Equity
0.02
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
-42.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
17.81%
Revenue last 5Y
-6.44%
Revenue Q/Q
14.09%
EPS Q/Q
-69.77%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
12.5%
Inst Trans
0.5%
ROA
-7%
ROE
-10%
ROC
-0.12%
Gross Margin
54%
Oper. Margin
-22%
Profit Margin
-19%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.65-1.49
52W High
-
52W Low
-
RSI
41
Rel Volume
0.39
Avg Volume
1.84M
Volume
712.36K
Perf Week
-13.74%
Perf Month
-4.68%
Perf Quarter
27.52%
Perf Half Y
10.68%
-
-
-
-
Beta
2.012
-
-
Volatility
0.03%, 0.08%
Prev Close
0.93%
Price
0.8799
Change
-8.34%
AMRN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.25 | 1.61 | 1.47 | 0.92 | 0.76 | |
| Net income per share | -0.07 | -0.05 | 0.02 | -0.26 | -0.15 | |
| Operating cash flow per share | -0.03 | -0.06 | -0.17 | -0.45 | 0.02 | |
| Free cash flow per share | -0.03 | -0.06 | -0.17 | -0.45 | 0.02 | |
| Cash per share | 1.88 | 1.31 | 1.15 | 0.77 | 0.79 | |
| Book value per share | 1.78 | 1.64 | 1.68 | 1.48 | 1.35 | |
| Tangible book value per share | 1.73 | 1.61 | 1.63 | 1.43 | 1.31 | |
| Share holders equity per share | 1.78 | 1.64 | 1.68 | 1.48 | 1.35 | |
| Interest debt per share | 0.19 | 0.48 | 0.55 | 0.05 | 0.02 | |
| Market cap | 7.34B | 1.87B | 1.33B | 485.4M | 354.66M | |
| Enterprise value | 6.76B | 1.69B | 1.12B | 277.75M | 163.62M | |
| P/E ratio | -324.31 | -103.71 | 172.66 | -4.59 | -5.98 | |
| Price to sales ratio | 17.09 | 3.04 | 2.29 | 1.31 | 1.15 | |
| POCF ratio | -784.11 | -85.85 | -20.06 | -2.7 | 51.35 | |
| PFCF ratio | -620.06 | -84.86 | -20.06 | -2.69 | 55.66 | |
| P/B Ratio | 12.07 | 2.97 | 2 | 0.82 | 0.64 | |
| PTB ratio | 12.07 | 2.97 | 2 | 0.82 | 0.64 | |
| EV to sales | 15.73 | 2.75 | 1.93 | 0.75 | 0.53 | |
| Enterprise value over EBITDA | -426.3 | -115.29 | 44.7 | -3.08 | -11.3 | |
| EV to operating cash flow | -721.65 | -77.67 | -16.89 | -1.54 | 23.69 | |
| EV to free cash flow | -570.67 | -76.78 | -16.89 | -1.54 | 25.68 | |
| Earnings yield | 0 | -0.01 | 0.01 | -0.22 | -0.17 | |
| Free cash flow yield | 0 | -0.01 | -0.05 | -0.37 | 0.02 | |
| Debt to equity | 0.1 | 0.29 | 0.32 | 0.03 | 0.02 | |
| Debt to assets | 0.07 | 0.19 | 0.2 | 0.02 | 0.01 | |
| Net debt to EBITDA | 36.9 | 12.14 | -8.39 | 2.3 | 13.19 | |
| Current ratio | 3.53 | 2.86 | 2.37 | 2.66 | 2.8 | |
| Interest coverage | -3.66 | -7.55 | 172.71 | -6.16K | -2.18K | |
| Income quality | 0.41 | 1.21 | -8.61 | 1.7 | -0.12 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.1 | -0.4 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.75 | 0.18 | 0.24 | 0.32 | 0.29 | |
| Research and developement to revenue | 0.08 | 0.06 | 0.05 | 0.08 | 0.06 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0.26 | 0.01 | 0 | 0 | -0.08 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2.88 | -0.12 | 0 | -0.19 | -0.18 | |
| Stock based compensation to revenue | 0.07 | 0.07 | 0.06 | 0.07 | 0.05 | |
| Graham number | 1.63 | 1.32 | 0.86 | 2.97 | 2.11 | |
| ROIC | -0.04 | -0.03 | 0.02 | -0.15 | -0.03 | |
| Return on tangible assets | -0.03 | -0.02 | 0.01 | -0.12 | -0.07 | |
| Graham Net | 1.45 | 0.98 | 0.74 | 0.58 | 0.66 | |
| Working capital | 612.76M | 571.79M | 508.05M | 429.62M | 465.7M | |
| Tangible asset value | 593.01M | 613.69M | 643.55M | 573.55M | 532.79M | |
| Net current asset value | 581.06M | 540.72M | 477.76M | 398.25M | 445.39M | |
| Invested capital | 0.1 | 0.29 | 0.32 | 0.03 | 0.02 | |
| Average receivables | 91.48M | 135.5M | 159.11M | 147.32M | 132.28M | |
| Average payables | 43.79M | 77.91M | 110.4M | 89.76M | 58.68M | |
| Average inventory | 67.29M | 132.82M | 211.77M | 231.7M | 243.67M | |
| Days sales outstanding | 98.89 | 91.88 | 102.43 | 129.5 | 158.23 | |
| Days payables outstanding | 189.88 | 294 | 345.73 | 186.09 | 182.52 | |
| Days of inventory on hand | 291.82 | 524.45 | 706 | 658.89 | 894.62 | |
| Receivables turnover | 3.69 | 3.97 | 3.56 | 2.82 | 2.31 | |
| Payables turnover | 1.92 | 1.24 | 1.06 | 1.96 | 2 | |
| Inventory turnover | 1.25 | 0.7 | 0.52 | 0.55 | 0.41 | |
| ROE | -0.04 | -0.03 | 0.01 | -0.18 | -0.11 | |
| Capex per share | -0.01 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.23 | 0.21 | 0.2 | 0.16 | 0.18 | |
| Net income per share | 0 | -0.04 | -0.04 | -0.05 | -0.01 | |
| Operating cash flow per share | 0 | -0.02 | 0.02 | 0.02 | 0 | |
| Free cash flow per share | 0 | -0.02 | 0.02 | 0.02 | 0 | |
| Cash per share | 0.77 | 0.75 | 0.77 | 0.79 | 0.79 | |
| Book value per share | 1.49 | 1.44 | 1.4 | 1.35 | 1.35 | |
| Tangible book value per share | 1.44 | 1.39 | 1.35 | 1.31 | 1.3 | |
| Share holders equity per share | 1.49 | 1.44 | 1.4 | 1.35 | 1.35 | |
| Interest debt per share | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 | |
| Market cap | 483.38M | 609.27M | 485.34M | 375.74M | 355.38M | |
| Enterprise value | 275.73M | 427.69M | 261.82M | 113.9M | 164.34M | |
| P/E ratio | 141.18 | -9.25 | -6.91 | -4.86 | -15.24 | |
| Price to sales ratio | 5.36 | 7.09 | 6.05 | 5.69 | 4.72 | |
| POCF ratio | 311.46 | -86.94 | 67.37 | 51.27 | -545.43 | |
| PFCF ratio | 507.03 | -86.94 | 67.59 | 51.28 | -305.7 | |
| P/B Ratio | 0.81 | 1.04 | 0.85 | 0.68 | 0.64 | |
| PTB ratio | 0.81 | 1.04 | 0.85 | 0.68 | 0.64 | |
| EV to sales | 3.06 | 4.97 | 3.27 | 1.72 | 2.18 | |
| Enterprise value over EBITDA | -39.66 | -25.8 | -82.77 | -5.9 | -42.06 | |
| EV to operating cash flow | 177.66 | -61.03 | 36.34 | 15.54 | -252.23 | |
| EV to free cash flow | 289.22 | -61.03 | 36.46 | 15.54 | -141.37 | |
| Earnings yield | 0 | -0.03 | -0.04 | -0.05 | -0.02 | |
| Free cash flow yield | 0 | -0.01 | 0.01 | 0.02 | 0 | |
| Debt to equity | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Debt to assets | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 29.87 | 10.95 | 70.67 | 13.57 | 48.89 | |
| Current ratio | 2.66 | 2.8 | 2.61 | 2.69 | 2.8 | |
| Interest coverage | -9.77K | -16.01 | 0 | 0 | 4.26 | |
| Income quality | 1.81 | 0.43 | -0.41 | -0.38 | 0.11 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.34 | 0.32 | 0.23 | 0.32 | 0.28 | |
| Research and developement to revenue | 0.06 | 0.07 | 0.07 | 0.08 | 0.07 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.39 | 0 | 0 | 0 | 0.78 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | -0.01 | |
| Capex to depreciation | -0.79 | 0 | -0.03 | 0 | -0.69 | |
| Stock based compensation to revenue | 0.07 | 0.06 | 0.02 | 0.05 | 0.06 | |
| Graham number | 0.27 | 1.15 | 1.16 | 1.2 | 0.66 | |
| ROIC | 0 | -0.03 | -0.04 | -0.04 | -0.02 | |
| Return on tangible assets | 0 | -0.02 | -0.02 | -0.02 | -0.01 | |
| Graham Net | 0.58 | 0.6 | 0.56 | 0.62 | 0.66 | |
| Working capital | 429.62M | 439.58M | 435.56M | 450.82M | 465.7M | |
| Tangible asset value | 573.55M | 563.72M | 548.75M | 533.47M | 532.79M | |
| Net current asset value | 398.25M | 408.43M | 415.61M | 431.63M | 445.39M | |
| Invested capital | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 127.18M | 132.11M | 127.98M | 122.57M | 127.98M | |
| Average payables | 78.88M | 61.69M | 56.54M | 53.84M | 53.06M | |
| Average inventory | 228.17M | 227.27M | 226.42M | 240.74M | 256.54M | |
| Days sales outstanding | 130.63 | 139.47 | 137.78 | 166.77 | 159.5 | |
| Days payables outstanding | 218.24 | 139.04 | 130.35 | 132.54 | 155.25 | |
| Days of inventory on hand | 772.71 | 534.15 | 544.86 | 632.04 | 760.96 | |
| Receivables turnover | 0.69 | 0.65 | 0.65 | 0.54 | 0.56 | |
| Payables turnover | 0.41 | 0.65 | 0.69 | 0.68 | 0.58 | |
| Inventory turnover | 0.12 | 0.17 | 0.17 | 0.14 | 0.12 | |
| ROE | 0 | -0.03 | -0.03 | -0.03 | -0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
AMRN Frequently Asked Questions
What is Amarin Corporation plc stock symbol ?
Amarin Corporation plc is a IE stock and trading under the symbol AMRN
What is Amarin Corporation plc stock quote today ?
Amarin Corporation plc stock price is $0.8799 today.
Is Amarin Corporation plc stock public?
Yes, Amarin Corporation plc is a publicly traded company.
Company Profile
- Volume Average 1.84M
- Market Capitalization 391.24M
- Employee 275
- CEO Mr. Patrick J. Holt
- Headquarters Dublin,IE
- IPO Date 1993-04-01
-
Website
https://www.amarincorp.com 
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
